| 05th week of 2010 patent applcation highlights part 44 |
| Patent application number | Title | Published |
|---|
| 20100028393 | Cosmetic Composition - Cosmetic composition comprising a continuous aqueous phase, a first dispersed, non-aqueous phase comprising hydrophobic colorant and a second dispersed, non-aqueous phase being substantially free of hydrophobic colorant; a method for preparing this composition and its use thereof. | 2010-02-04 |
| 20100028394 | COSMETIC COMPOSITION FOR MAKING UP AND/OR CARING FOR THE LIPS - The present invention is targeted at a cosmetic composition, in particular in stick form, formed of at least one liquid core comprising at least one fatty phase which is liquid at ambient temperature and held inside a solid sheath comprising at least one fatty substance which is solid at ambient temperature. | 2010-02-04 |
| 20100028395 | COMPOSITIONS CONTAINING N-ACETYLGLUCOSAMINE FOR USE IN DERMO-COSMETOLOGY AND AESTHETIC MEDICINE - A composition useful for cosmetic treatment of the skin containing N-acetylglucosamine and an alkaline metal sulphate in equivalent mass ratios between 1:0.5 and 1:3, optionally in association with hyaluronic acid or a salt thereof. | 2010-02-04 |
| 20100028396 | TISSUE SCAFFOLDS DERIVED FROM FORESTOMACH EXTRACELLULAR MATRIX - The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold. | 2010-02-04 |
| 20100028397 | Anti-Infective Protector - The present disclosure provides an anti-infective protector containing at least one anti-infective agent. The anti-infective protector provides for a range of benefits not appreciated in the prior art. | 2010-02-04 |
| 20100028398 | CELL IMPLANTATION TO PREVENT AND/OR TREAT HEARING LOSS - The present invention is directed to the prevention or treatment of sensorineural hearing loss by administering a therapeutically effective amount of an implantable composition comprising encapsulated living choroid plexus cells. | 2010-02-04 |
| 20100028399 | Use of Polymers - The present invention relates to the use of a thiol-group-containing polymer for preparing an implant for tissue augmentation, wherein the basis polymer is a polysaccharide. | 2010-02-04 |
| 20100028400 | PHARMACEUTICAL COMPOSITION ON THE BASIS OF STACHYTARPHETA SP., A PROCESS FOR OBTAINING THE SAME AND ITS USE FOR TREATING VITILIGO - This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plant of the | 2010-02-04 |
| 20100028401 | STEM CELL SOURCE FOR PROMOTING NEOVASCULARISATION - The Eph (erythropoietin-producing hepatocellular carcinoma) receptors and their cell surface anchored ligands, the Ephrins, comprise the largest of the receptor tyrosine kinases families with 14 receptors and 8 ligands. The receptors are subdivided into Eph-A and Eph-B categories and have known actions in the development of the vascular and nervous system. The present invention relates to an isolated mesenchymal stem cell selected from the group consisting of an isolated mesenchymal stem cell that expresses Ephrin-B2, an isolated mesenchymal stem cell that over-expresses Ephrin-B2, and an isolated mesenchymal stem cell that is genetically modified to increase Ephrin-B2 expression. The invention further relates to the various applications of the isolated mesenchymal stem cells of the present invention. | 2010-02-04 |
| 20100028402 | NANOPARTICLE-BASED ANTICOAGULANT - A method for preventing or treating a blood clotting disorder is disclosed. The method includes administering a therapeutic effective amount of at least one nanoparticle-based anticoagulant to a subject afflicted with blood clotting disorder or potentially afflicted with a blood clotting disorder, wherein the at least one nanoparticle-based anticoagulant is a substituted fullerene, polyamidoamine (PAMAM) dendrimer or combination thereof. | 2010-02-04 |
| 20100028403 | MEDICAL DEVICES FOR THERAPEUTIC AGENT DELIVERY - In various aspects, the present invention relates to implantable or insertable medical devices which release therapeutic agent into the body of a patient. | 2010-02-04 |
| 20100028404 | Compound and device for treating bone and/or cartilage defects - The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil. | 2010-02-04 |
| 20100028405 | MATRIX, CELL IMPLANTATION AND METHOD FOR THEIR PRODUCTION AND USE - The invention relates to porous matrices based on a biologically compatible polymer or polymer mixture, to a cell implantation that is established on said matrices and to additional cell implantation based on cell mixtures of hepatocytes and islets of Langerhans. The invention also relates to a method for producing porous matrices, to matrices obtained according to said method and to a special method for obtaining cells for the inoculation of an implantable matrix. | 2010-02-04 |
| 20100028406 | TOPICAL DRUG DELIVERY BY IONTOPHORESIS - The invention generally concerns methods of topical drag delivery. Delivery according to the invention may be via electrotransport of compounds through the skin, for example by iontophoresis. In certain embodiments improved methods for the delivery of compounds, such as antimicrobial agents are described. | 2010-02-04 |
| 20100028407 | LAYERED BIO-ADHESIVE COMPOSITIONS AND USES THEREOF - The invention generally provides compositions and methods for promoting and enhancing wound closure and healing. Specifically, the invention provides a biologic composition which comprises a support layer which serves as transport scaffold, for example made of gelatin, which is coated or impregnated with a bio-adhesive molecule such as rose bengal or glyceraldehyde. The composition can also comprise an artificial or biological matrix, optionally processed (i.e. cleaned and coated with extracellular matrix proteins) to enhance cell attachment and survival. The composition can further comprise a monolayer of epithelial, endothelial cells or mesenchymal cells. The invention provides methods for using the compositions for treating wounds due to disease, trauma or surgery. Specific methods for treating ocular wounds are provided. | 2010-02-04 |
| 20100028408 | Method for sterilizing unheated raw honey, a honey-based wound care preparation, a wound care treatment product, and a biscuit based on honey - The invention relates to a method for sterilizing raw, unheated honey, wherein the raw, unheated honey is sterilized by ozonizing it by using an ozone generator. The invention also relates to a honey-based wound care preparation, wherein said preparation comprises raw, unheated ozonized honey that has been ozonized by a method according to the invention. The invention also relates to a wound care treatment product comprising a honey-based preparation, wherein the said wound care treatment product comprises a preparation according to the invention. Finally, the invention relates to a biscuit based on honey and food fibres and/or by-products of food fibres, wherein the biscuit is prepared from ozonized food fibres and/or by-products of food fibres and raw, unheated ozonized honey that has been ozonized by a method according to the invention. | 2010-02-04 |
| 20100028409 | Barrier Membranes For Guided Bone Regeneration - A barrier membrane for guided bone regeneration and a method of manufacturing the same are provided. The barrier membrane for guided bone regeneration that is made of silver, gold, or gold alloy includes a substrate having texture including protrusions with a predetermined shape, a polymer layer formed by coating an upper surface of the substrate with polymer solution, and a bio-ceramic layer formed by coating a lower surface of the substrate. It is possible for the barrier membrane for guided bone regeneration to secure biocompatibility, exclusion and sealing of cells, space maintenance, connectivity with tissues, and easiness of using the barrier membrane which are required for guided bone/tissue regeneration (GBR/GTR). | 2010-02-04 |
| 20100028410 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 2010-02-04 |
| 20100028411 | ADHESIVE SKIN PATCH AND METHOD FOR EVALUATION OF ADHESIVE SKIN PATCH - Disclosed is an adhesive skin patch having an SIS block copolymer as an adhesive component, which has an improved handling property and can reduce irritation to a user. The adhesive skin patch comprises a flexible substrate and an adhesive layer laminated on the substrate, wherein the adhesive layer comprises a styrene-isoprene-styrene block copolymer. In the adhesive skin patch, the tan δ value of the adhesive agent as determined by measuring a dynamic viscoelasticity at 32° C. satisfies a requirement represented by the following formula 1 at least one frequency laying between 0.04 to 0.25 Hz. 0.25x+0.05≦y≦0.25x+0.10 (formula 1) [wherein x represents a frequency (Hz); and y represents a tan δ value.] | 2010-02-04 |
| 20100028412 | TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING WATER-SOLUABLE ACTIVE INGREDIENTS - The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure. | 2010-02-04 |
| 20100028413 | SKIN TREATMENT STRIP - The skin treatment strip includes a base liner and an applicant liner coupled to the base liner by an adhesive. The skin treatment strip further includes a chemical layer sandwiched between the base liner and the applicant liner that is reactive to a skin blemish. The chemical layer includes a weak acid such as hydrogen peroxide for treating the skin blemish, a base such as sodium hydroxide for balancing skin pH and preventing skin irritation, a sugar-based alcohol such as glycerin for soothing the skin and a water-based carrier. Preferably, the adhesive is used to maintain contact of the chemical layer with the skin blemish upon application of the applicant liner. | 2010-02-04 |
| 20100028414 | COMBINATION OF TYROSINE KINASE INHIBITOR AND HER-2/NEU FOR CANCER THERAPY - A method of treating cancer is described comprising administration of a 4-quinazolineamine and a vaccine targeting the HER-2/neu molecule, as well as a pharmaceutical combination comprising 4-quinazolineamines and a vaccine targeting the HER-2/neu molecule. | 2010-02-04 |
| 20100028415 | Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 2010-02-04 |
| 20100028416 | DRUG CARRIERS - Compositions that can include a carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell. | 2010-02-04 |
| 20100028417 | USE OF SUBSTITUTED GLYCERIN DERIVATIVES FOR PRODUCING A PHARMACEUTICAL PREPARATION - A compound of the formula (1) or pharmaceutically acceptable salts thereof can be used for producing a pharmaceutical preparation for preventing or treating cancerous diseases, pathological sequelae of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal disorders, hepatic insulin resistance in diabetes mellitus, liver damage associated with Wilson's disease and/or sideroses, ischemic reperfusion damage, for use as an antidote to environmental toxins and prescription drug intoxication, for prolonging the retention time of drugs in the organism, and/or for combating toxic side effects on administration of chemotherapeutic agents. B | 2010-02-04 |
| 20100028418 | GAINAC SPECIFIC BINDING MOLECULES AND USES THEREOF - The present invention provides among others means and methods for detecting terminal GalNAc containing molecules. A preferred molecule for detecting said structures is a molecule comprising a carbohydrate binding part of MGL. | 2010-02-04 |
| 20100028419 | MEMBRANE(S) AND USES THEREOF - There is provided at least one agent delivery vehicle comprising at least one membrane of cubic structure or derivable from a membrane of cubic structure, methods for preparing them, and their use for transport of at least one foreign agent. In particular, the agent delivery vehicle may be in the form of at least one organelle, agent delivery particle and/or liposome. The invention further provides kits and methods of treatment using the agent delivery vehicle(s). | 2010-02-04 |
| 20100028420 | CONTROLLED RELEASE COMPOSITION AND PROCESS - A composition for encapsulation and controlled release comprises a water-insoluble matrix comprising a host molecule that is non-covalently crosslinked by multi-valent cations, that is non-polymeric, that has more than one carboxy functional group, that has at least partial aromatic or heteroaromatic character, and that comprises at least one pterin or 5-substituted pterin moiety. The composition can further comprise a guest molecule (for example, a drug) that can be encapsulated within the matrix and subsequently released. | 2010-02-04 |
| 20100028421 | Solid Oral Dosage Form Containing an Enhancer - The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form. | 2010-02-04 |
| 20100028422 | Pharmaceutical Compositions and Methods for Treating or Preventing Oxalate-Related Disease - The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. | 2010-02-04 |
| 20100028423 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 2010-02-04 |
| 20100028424 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 2010-02-04 |
| 20100028425 | PHARMACEUTICAL COMPOSITION OF ATOVAQUONE - The present invention relates to immediate release pharmaceutical compositions for oral administration comprising micronized atovaquone particles and at least one drug, wherein about 90% of the atovaquone particles have a volume diameter between about 4 μm to about 8 μm; and having a uniform release profile after a storage for at least three months at 40° C. and 75% relative humidity. | 2010-02-04 |
| 20100028426 | TIME-SPECIFIC DELAYED/PULSATILE RELEASE DOSAGE FORMS. - A time-specific delayed/pulsatile release dosage form which comprises:
| 2010-02-04 |
| 20100028427 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 2010-02-04 |
| 20100028428 | FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-- BETA-PHENYL-3-QUINOLINEETHANOL - The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1 -naphthalenyl-beta-phenyl-3-quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation. | 2010-02-04 |
| 20100028429 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 2010-02-04 |
| 20100028430 | MATERIAL AND MANUFACTURING METHOD OF BIOACTIVE PROTEIN-CALCIUM PHOSPHATE COMPOSITE - Disclosed are a bioactive protein-calcium phosphate ceramic composite for surface modification of a substrate for use as a substitute in the treatment of musculoskeletal disorders, and a preparation method thereof. The bioactive protein-calcium phosphate ceramic composite is prepared by mixing an aqueous solution of calcium phosphate and a protein, and impregnating the calcium phosphate and the protein in the resulting aqueous solution to co-precipitate them on a substrate, such as metals, ceramics and polymers, wherein the substrate is patterned, and different proteins are impregnated in at least two regions of the patterned regions. | 2010-02-04 |
| 20100028431 | COMPOSITIONS AND METHODS FOR THERAPEUTIC USE - A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: | 2010-02-04 |
| 20100028432 | FORMULATIONS OF ACTIVE PRINCIPLES INCORPORATED IN SLNS SUITABLE FOR TRANSDERMAL ADMINISTRATION - The present invention relates to formulations suitable for transdermal administration characterized by containing SLNs which contain active principles with a very short half-life and/or drugs with high activity. | 2010-02-04 |
| 20100028433 | IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND HEPATITIS B VIRUS IMMUNOGEN AND METHODS OF USING THE SAME - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) against Hepatitis B virus (HBV)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 2010-02-04 |
| 20100028434 | Temperature controlled and pH dependent self gelling biopolymeric aqueous solution - The present invention relates a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises: an acidic water-based medium, 0.1 to 10% by weight of a pH-gelling acid-soluble biopolymer; and 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4. The liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from 10 to 70° C. The present invention also relates to a method for preparing the composition and uses thereof. | 2010-02-04 |
| 20100028435 | INJECTABLE HYDROGEL WITH AN ENHANCED REMANENCE AND WITH AN ENHANCED ABILITY TO CREATE VOLUME - An injectable hydrogel includes a hydrogel matrix based on (a) single-phase-type cross-linked biopolymer(s), characterized in that previously cross-linked biopolymer hydrogel particles are co-cross-linked with the matrix. A method of and a process for production of the above-mentioned hydrogel are also disclosed. | 2010-02-04 |
| 20100028436 | POLYMER MATRIX, USES THEREOF AND A METHOD OF MANUFACTURING THE SAME - The present invention relates to a polymer matrix, characterized in that it comprises a) an electron donating constituent and b) metal particles comprising at least one metal chosen from palladium, gold, ruthenium, rhodium, osmium, iridium, and platinum. The polymer matrix makes it possible to improve the biocompatibility and antimicrobial properties of substrates coated with said polymer matrix. | 2010-02-04 |
| 20100028437 | Hyaluronic Acid-Based Gels Including Lidocaine - Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2010-02-04 |
| 20100028438 | Hyaluronic Acid-Based Gels Including Lidocaine - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2010-02-04 |
| 20100028439 | Nanoparticulate stabilized anti-hypertensive compositions - The present invention is directed to anti-hypertensive compositions comprising a nanoparticulate temocapril, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate temocapril particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases. | 2010-02-04 |
| 20100028440 | DRYING OF DRUG-CONTAINING PARTICLES - A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes. | 2010-02-04 |
| 20100028441 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 2010-02-04 |
| 20100028442 | METHODS OF THERAPEUTIC TREATMENT OF EYES - Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids) and therapeutic compositions for use in treating eye conditions. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases. | 2010-02-04 |
| 20100028443 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions. | 2010-02-04 |
| 20100028444 | USE OF WATER-DISPERSIBLE CAROTENOID NANOPARTICLES AS TASTE MODULATORS, TASTE MODULATORS CONTAINING WATER-DISPERSIBLE CAROTENOID NANOPARTICLES, AND, METHOD FOR TASTE MODULATION - Use of at least one type of water-dispersible carotenoid nanoparticles as taste modulators in compositions of matter; process for taste modulation of compositions of matter in which at least one type of water-dispersible carotenoid nanoparticles is added to compositions of matter; and also taste modulators for compositions of matter comprising | 2010-02-04 |
| 20100028445 | POLYMER - The invention provides compositions comprising a polyamidoamine (PAA) polymer comprising a pendant disulphide, sulphydryl, or activated sulphydryl moiety, and methods for their manufacture. The invention extends to the use of such polyamidoamine polymers to form cross-linked compositions, and hydrogels comprising the same, and the use of such compositions in various biological and non-biological applications, such as the delivery of biomolecules to target sites, and for tracking fluid flows. The invention also provides carrier particles, which may be used to deliver biomolecules, and to methods of treatment. The invention also provides a fluid tracking system for monitoring fluid flow. | 2010-02-04 |
| 20100028446 | TRANSPORT OF DRUGS VIA THE BLOOD-BRAIN BARRIER BY MEANS OF APOLIPOPROTEINS - Combination preparations comprising at least one apolipoprotein as one component, and a medicinal agent to be transported via the blood-brain barrier to the central nervous system as a further component. The components are administered simultaneously, separately or sequentially. A method for administering a medicinal agent to the central nervous system is also provided. | 2010-02-04 |
| 20100028447 | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs - The present invention generally relates to pharmaceutical compositions for the intranasal, buccal, or sublingual administration of metanicotine analogs. | 2010-02-04 |
| 20100028448 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 2010-02-04 |
| 20100028449 | FERMENTED MILK PRODUCT AND USE THEREOF - The present invention relates to an oral formulation comprising a microcapsule containing bacteria and a fermented milk carrier. There is also provided a method of medical treatment of an inflammatory gastrointestinal disease or disorder in a subject in need thereof, comprising detecting the presence of inflammatory gastrointestinal disease or disorder in the subject, wherein if inflammatory gastrointestinal disease or disorder is detected, then administering the formulation of the present invention to the subject. | 2010-02-04 |
| 20100028450 | TOLEROGENIC BIODEGRADABLE ARTIFICIAL ANTIGEN PRESENTING SYSTEM - An artificial antigen presenting system is presented. The herein presented microspheres combine negative regulators individually or at varying combinations along with MCH molecules and can induce antigen specific tolerance. The herein described methods provide for the construction of artificial biodegradable microsomes containing MHC: peptide complexes, accessory molecules, co-stimulatory molecules, adhesion molecules, and other molecules relevant to T cell binding or modulation. Additionally, the present invention is directed to compositions and methods for treating conditions which would benefit from modulation of T cell response, for example, autoimmune disorders, allergies, cancers, viral infections, and graft rejection. | 2010-02-04 |
| 20100028451 | SILK MICROSPHERES FOR ENCAPSULATION AND CONTROLLED RELEASE - A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments. | 2010-02-04 |
| 20100028452 | DELIVERY SYSTEM FOR ACTIVE COMPONENTS AS PART OF AN EDIBLE COMPOSITION HAVING PRESELECTED TENSILE STRENGTH - A delivery system for inclusion in an edible composition is formulated to have at least one active component encapsulated within an encapsulating material, whereby the delivery system has a tensile strength suitable for delivering the active component at a desired release rate. | 2010-02-04 |
| 20100028453 | MULTI -FUNCTIONAL NANOPARTICLES PARTIALLY-DEPOSITED WITH GOLD FILM - Disclosed herein are multifunctional nanoparticles, comprising: polymer nanoparticles formed by loading a drug into a polymer; a gold thin film deposited on a portion of the surface of the polymer nanoparticles; and an antibody to a substance expressed on the surface of a cell to which the drug is to be delivered, the antibody being conjugated to the gold thin film. Also disclosed is a method for preparing multifunctional nanoparticles, the method comprising the steps of: loading a drug into a polymer to prepare polymer nanoparticles; depositing a portion of the surface of the polymer nanoparticles with a gold thin film; conjugating to the gold thin film an antibody to a substance expressed on the surface of a cell to which the drug is to be delivered; and separating from the resulting nanoparticles those in which a portion of the surface of the polymer nanoparticles is deposited with the gold thin film and conjugated with the antibody. Furthermore, disclosed are a composition containing the multifunctional nanoparticles and a method for diagnosing and treating disease using the composition. | 2010-02-04 |
| 20100028454 | Preparation method for biodegradable micro-particles containing drugs - The disclosure provides a method to form sustained release drug-containing microparticles with a biodegradable polymer. The method involves forming a polymer-drug-organic solvent phase, and dispersing the polymer-drug-organic solvent phase in an aqueous suspension of an inorganic gel, which may be hydroxyapatite. The hydroxyapatite appears to coat the polymer-drug-solvent droplets to prevent them coalescing. The solvent then evaporates with stirring of the dispersion, at which time the droplets solidify to drug-containing microparticles. The inorganic gel allows suitably small microparticles to form without use of an organic emulsifier. | 2010-02-04 |
| 20100028455 | NUTRITIONAL SUPPLEMENT - A nutritional supplement derived from skeletal tissue found in bony and cartilaginous fish has been found to be useful in the treatment of mineral deficiencies, in particular calcium deficiency, and additionally, in the treatment of arthritis, kidney stones, and gout in animals, including humans. A nutritional supplement composition and a pharmaceutical composition containing the nutritional supplement are also provided. The nutritional supplement contains 300,000 to 400,000 mg/kg calcium, 100 to 150 mg/kg phosphorous, 10 to 20 mg/kg magnesium, and 1,500 to 2,000 mg/kg sodium. | 2010-02-04 |
| 20100028456 | BROAD-SPECTRUM ANTIVIRAL COMPOSITION WITH EXCELLENT PRESERVATION STABILTY - A composition for a broad-spectrum antiviral agent with excellent preservation stability, which comprises a pure chlorine dioxide solution comprising a chlorine dioxide gas dissolved therein, a chlorite, and a pH adjuster. | 2010-02-04 |
| 20100028457 | AGENT FOR PREVENTION OR TREATMENT OF BLOOD GLUCOSE LEVEL ELEVATION - An object is to find a natural material having an activity of preventing the elevation of blood glucose level and to provide a means which is able to prevent or treat the diabetes and there is provided an agent for prevention or treatment of the elevated blood glucose level where a compound containing soluble silica and/or strontium is an active ingredient. | 2010-02-04 |
| 20100028458 | MILD COMPOSITION FOR SKIN DISINFECTION - The present invention discloses compositions for aqueous skin disinfection comprising hydrogen peroxide in a concentration of at least 0.1% to 10% (w/w), preferably 0.2-6%, and an N-acylated amino acid and/or peptide in the range of 0.1-20% (w/w), preferably 0.1-10%, more preferably 0.2-8%, and most preferably 0.2-5% (w/w). The N-acylated amino acid composition may be N-acylated glutamic acid and/or an N-acylated wheat protein hydro-lysate, or a salt thereof. | 2010-02-04 |
| 20100028459 | NUTRITIONAL SUPPLEMENT COMPOSITION FOR TREATMENT OF OCULAR DISEASES - The present invention relates to an antioxidant and lutein supplement composition which inter alia decreases visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in people with early age-related macular degeneration. | 2010-02-04 |
| 20100028460 | IMPROVEMENTS IN RELATION TO CANCER THERAPY - The present invention relates to an improved assay for identifying compounds that may be of use in conjunction with cancer chemotherapeutic agents and anti-proliferative agents, to improve efficacy of such agents and/or render effective compounds with relatively little therapeutic activity. There is also provided a class of compounds of formula (I) and retinoids identified by said assay which may be used in a combination therapy, with current and novel agents, to treat cancers and other diseases associated with abnormal host cell proliferation, such as psoriasis. | 2010-02-04 |
| 20100028461 | Gamma-butyrolactone compound and pharmaceutical composition thereof - A γ-butyrolactone compound as shown in Formula (I) and pharmaceutical composition thereof: | 2010-02-04 |
| 20100028462 | STABLE AQUEOUS SOLUTIONS OF SILANE QUAT AMMONIUM COMPOUNDS - Stable aqueous compositions of silane quaternary ammonium compounds are provided by diluting an alkanol solution of the silane quaternary ammonium compound in water with at least one nonionic surfactant. The weight ratio of the silane quaternary ammonium compound and nonionic surfactant is provided to yield a composition which can remain stable in dilute aqueous compositions, can be applied to any surface and dry quickly to provide an anti-microbial film. The addition of an alkali metal bicarbonate salt to the composition improves the anti-microbial properties as well as the drying time of the composition. | 2010-02-04 |
| 20100028463 | EXTRACT OF STEWARTIA KOREANA AND USE THEREOF - The present invention relates to an extract of | 2010-02-04 |
| 20100028464 | USE OF SAFFRON AND/OR SAFRANAL AND/OR CROCIN AND/OR PICROCROCIN AND/OR DERIVATIVES THEREOF AS A SATEITY AGENT FOR TREATMENT OF OBESITY - Use of saffron and its active ingredients, such as safranal and/or picrocrocin and/or crocin and/or derivatives thereof, for the production of an active satiation agent for the treatment of problems of overweight. | 2010-02-04 |
| 20100028465 | COMPOSITION FOR AMELIORATING CEREBRAL FUNCTION - Provided is a substance which is a safe material such as a food component and an extract of a natural product and has a stronger effect of ameliorating a cerebral function (effect of ameliorating a metabolism of monoamines as an intracerebral neurotransmitter and ameliorating deterioration in memory and learning due to hypofunction of a cholinergic neuron). The present invention provides a composition for ameliorating a cerebral function, comprising an alkali-stable lipid from an acetic acid bacterium, N-acylsphinganine or N-2′-hydroxypalmitoyl-sphinganine, as an active ingredient. | 2010-02-04 |
| 20100028466 | CAROTENOID COMPOSITIONS CONTAINING MODIFIED GUM ACACIA - The present invention relates to compositions containing modified gum acacia and carotenoids, wherein the gum acacia has been subjected to a heat-treatment at a temperature between 100° C. and 115° C. for 1 to 38 hours, wherein the composition comprises less than 40 weight-% oil. It has been found that the compositions according to the invention allow to produce emulsions having a very high color intensity, color stability. These compositions can be used for the enrichment, fortification and/or coloration of food beverages, animal feed, cosmetics or pharmaceutical compositions. The present invention also refers to the preparation of such compositions, wherein it has been found that the emulsification time in the manufacturing process of the compositions can be reduced when using a modified gum acacia in carotenoid compositions with less than 40 weight-% oil. The present ‘invention furthermore refers to a process for the manufacture of a beverage by mixing the compositions with ingredients of beverages. The present invention also refers to beverages obtainable by this process. | 2010-02-04 |
| 20100028467 | Composition Comprising Ginsenosides Isolated From The Extract Of Processed Ginseng For Preventing And Treating Thrombotic Disease - The present invention relates to compositions containing an extract of processed | 2010-02-04 |
| 20100028469 | Extracts of Cranberry and Methods of Using Thereof - The present disclosure relates in part to extracts of cranberry ( | 2010-02-04 |
| 20100028470 | ISOLATED EXTRACT OF WALNUTS, METHOD FOR ITS OBTENTION AND ITS USE - The invention refers to an isolated extract of walnuts of high efficiency and stability over time useful for the manufacture of a medicament for the treatment of viral, fungal and bacterial diseases, which is characterized in that it is obtained from a process comprising: i) Collecting unripe walnut fruits as raw material; ii) Preparing the raw material for the extraction; iii) Freezing the raw material prepared in the previous step; iv) Drying; v) Extracting in a time lower than 10 minutes; vi) Filtration; and vii) Final packaging. | 2010-02-04 |
| 20100028471 | COSMETIC USE OF ACTIVE AGENTS THAT STIMULATE MATRIPTASE EXPRESSION - The present invention relates to a cosmetic process for caring for human skin, intended to moisturize it and/or to protect it against drying out, comprising the topical application to the skin of a composition containing at least one active agent that stimulates the expression of the matriptase MT/SP1. It also relates to the cosmetic use of such an active agent for moisturizing human skin and/or protecting it against drying out. It further relates to the use of such an active agent to manufacture a pharmaceutical composition intended to prevent and/or alleviate skin tautness, stinging and/or itching and/or lip chapping. The active agents are extracts of | 2010-02-04 |
| 20100028472 | HERBAL COMPOSITION AND PROCESS FOR ITS PREPARATION - A herbal composition comprising a therapeutically effective amount of the extract of | 2010-02-04 |
| 20100028473 | BODY FAT-REDUCING AGENT - Described are body fat-reducing agents containing a processed pueraria flower as an active component. The body fat-reducing agent has a superior body fat-reducing effect. Furthermore, the body fat-reducing agent may contain at least one of a lipid absorption suppressing component and a lipid metabolism promoting component. A food product, which contains the body fat-reducing agent, provided according to the present invention has superior effects of preventing body fat accumulation and reducing body fat. | 2010-02-04 |
| 20100028474 | SESAME SEED DERIVED PIGMENTS - The invention describes reduced sesame seed derived pigments and methods to prepare such pigments. | 2010-02-04 |
| 20100028475 | COMPRESSION MOLDING METHOD AND DEVICE THEREFOR - A compression molding method capable of preventing contamination of abrasion powders generated by scoring to thereby improve the product yield is provided. The compression molding method, including a fixed mold and a movable mold arranged opposite each other, includes: contacting a slide board connected with a movable die plate on the movable mold side via a spring, with the parting face of the fixed mold by a spring force; further advancing the movable mold after injecting resin into a cavity in the mold, and compressing and molding the resin filled in the cavity by a core, provided in the movable mold, penetrating through the slide board. A resin film is disposed between the fixed mold and the slide board, and one surface of the resin in the cavity is compressed by the core via the resin film. | 2010-02-04 |
| 20100028476 | SYSTEM FOR MANUFACTURING INTEGRATED SOCKETS IN BIAXIALLY ORIENTED PLASTIC PIPES - An example system is described for the integrated manufacturing of sockets in oriented pipes, with the possibility of regulating and distributing at will the thicknesses of the socket and making it possible to reinforce the traditionally weaker zones, without increasing the manufacturing process time. The system includes a support body, a slide block sliding axially on the inside of the body with a conical inner end, a heater, and a slide rod for pushing the corresponding blank. The slide rod has an axial and central orifice for the introduction of expansion and cooling fluid, whilst the slide block has orifices for the intake of a lubricating fluid. | 2010-02-04 |
| 20100028477 | DENTURE FORMING MACHINE FOR DENTAL USE - A denture forming apparatus for dental use includes clamps for protruding from and retracting to opposing sides in order to clamp or unclamp opposing side portions of the flask, thereby fixing or unfixing the flask; a pressing unit placed above the clamps to charge the resin, contained in a resin-filling pipe, into the flask under a predetermined pressure; and a control unit for controlling the operation of the clamps and controlling the pressing unit to descend at a predetermined rate of descent according to a type of the resin contained in the resin-filling pipe. The denture forming apparatus can be used irrespective of the type of resin since the speed of the pressing unit can be regulated. Accordingly, it is possible to realize an improvement over the conventional art, which can use only a designated type of resin. | 2010-02-04 |
| 20100028478 | POWDER PRESS - A powder press, with a press frame, which comprises an upper and lower frame section, an upper linear drive attached to the upper frame section and a lower linear drive attached to the lower frame section, wherein the drives are connected to an upper and lower punch plate or a die table, respectively, wherein the punch plates have a clamping system for an upper or a lower punch, a die clamping system on a die table with a die, and at least one force measuring device for measuring the pressing force on at least one punch, characterized in that at least one force measuring device is disposed between a punch plate and the associated clamping system. | 2010-02-04 |
| 20100028479 | APPARATUSES AND METHOD - An apparatus comprises a conveying device provided with seat elements arranged for receiving objects, the seat elements being movable along a curved path, and a further conveying device provided with a transferring arrangement arranged for delivering the objects to, and/or removing the objects from, the conveying device, wherein the transferring arrangement comprises coupling elements arranged for engaging the seat elements in such a way that the seat elements and the transferring arrangement are maintained mutually coupled along a portion of the curved path. | 2010-02-04 |
| 20100028480 | Connection Device for a Moulding Core for Producing a Fibre Composite Component, in Particular for Aerospace - The present invention relates to a connection device ( | 2010-02-04 |
| 20100028481 | Nozzle for an Injection Molding Apparatus - A nozzle for an injection molding apparatus is provided. The injection molding apparatus has a mold component that defines a mold cavity and a gate into the mold cavity. The nozzle includes a nozzle body, a heater, a tip, a tip retainer, and a nozzle seal piece. The nozzle body defines a nozzle body melt passage therethrough that is adapted to receive melt from a melt source. The heater is thermally connected to the nozzle body for heating melt in the nozzle body. The tip defines a tip melt passage therethrough that is downstream from the nozzle body melt passage, and that is adapted to be upstream from the gate. The tip retainer is removably connected with respect to the nozzle body. The nozzle seal piece is connected with respect to the nozzle body. The material of nozzle seal piece has a thermal conductivity that is less than at least one of the thermal conductivity of the material of the tip and the thermal conductivity of the material of the tip retainer. | 2010-02-04 |
| 20100028482 | Injection Molding Machine and Heat-Insulating Structure of Barrel Thereof - This invention discloses an injection molding machine and a heat-insulating structure of a barrel thereof. The heat-insulating structure covers the barrel of the injection molding machine. The heat-insulating structure includes a plurality of heat-insulating units and a plurality of heat-resistant interlinings. The heat-insulating units are disposed on an outer surface of the barrel in turn along an axial direction of the barrel. The heat-resistant interlinings are located between the heat-insulating units and connect the heat-insulating units, respectively. Each heat-insulating unit includes a heat-resistant layer, a heat-insulating material layer, and an insulating layer in turn. The heat-resistant layer covers the outer surface of the barrel of the injection molding machine. | 2010-02-04 |
| 20100028483 | SOLID EDIBLE PRODUCT FOR A PET - The present invention relates to a solid edible product for a pet having a moisture content of less than or equal to 10% comprising fat, a probiotic micro-organism and optionally a sweetener, a palatant and/or bulking material. The edible product may contain other ingredients. The invention also relates to a pet food product which comprises such a solid edible product as well as the solid edible product for improving or maintaining the health of a pet animal. | 2010-02-04 |
| 20100028484 | METHODS FOR PRODUCING LIPIDS FROM ETHANOL PRODUCTION CO-PRODUCTS BY INTRODUCING LIPID PRODUCING MICROORGANISMS - Methods for producing a lipid rich product from a feedstock utilized in wet and dry milling processes for producing ethanol, the method include mixing a culture of lipid producing microorganisms with the feedstock, wherein the feedstock includes co-products of ethanol production and/or biomass; producing lipids within the lipid producing microorganisms; lysing the microorganisms; and isolating the lipid rich product. | 2010-02-04 |
| 20100028485 | TALAROMYCES EMERSONII ENZYME SYSTEMS - The invention relates to strains of | 2010-02-04 |
| 20100028486 | BUBBLE STABILIZER AND SPARKLING BEVERAGE CONTAINING THE SAME - The object is to improve the bubble retention in a sparkling beverage such as a malt alcoholic beverage including a beer and a sparkling liquor, a sparkling alcoholic beverage produced without any malt and a carbonated refreshing beverage including a soda pop and a cream soda. Disclosed is a bubble stabilizer comprising, as an active ingredient, a water-soluble soybean polysaccharide which is produced by the heat-extraction from a soybean or a processed product of a soybean at a pH lower than the isoelectric point of a soybean protein and ranging from 2.4 to 4.0 at a temperature of 100° C. or higher. The bubble stabilizer can be added to a malt alcoholic beverage such as a beer and a sparkling liquor, a sparkling alcoholic beverage produced without any malt or a carbonated refreshing beverage such as a soda pop and a lemon soda to thereby improve the bubble retention in the beverage. | 2010-02-04 |
| 20100028487 | Method of producing vinegar and vinegar produced by this method - Provided are a method of producing a vinegar which can be utilized for a wide range of use such as drinking and cooking by reducing an unpleasant smell peculiar to a vinegar manufactured from a bran-containing raw material; and a vinegar produced by the method. Specifically, provided are a method of producing a vinegar including using a bran-containing raw material; and allowing to contain ammonia and a sugar into the vinegar so that an ammonia concentration is 40 to 250 mg/100 ml and a sugar concentration is to 50 g/100 ml, to thereby reduce a peculiar unpleasant smell; the vinegar produced by the method; and a food or beverage containing the vinegar. | 2010-02-04 |
| 20100028488 | ALGAL BIOMEAL-BASED PALATABILITY ENHANCER AND METHOD OF USE AND MANUFACTURE THEREFOR - An animal food palatability enhancing composition that includes a manufactured edible substrate comprising a texture; and a delipidated microbial biomeal, wherein the delipidated component comprises about 2% to about 4% docosahexaenoic acid (DHA) by weight and wherein the palatability enhancer improves palatability of animal food products. Also provided is a method for optimizing palatable components of microbial biomeal comprising: fermenting microbial aquaculture products; lysing microbial cells; extracting natant lipids to produce a waste product, wherein the microbial biomeal; elucidating the mechanisms of the chemical constituents in microbial aquaculture products; modifying the microbial biomeal to fit predetermined texture and flavor specifications; and characterizing a nutritional value of the microbial biomeal; wherein formulation of pet food palatable components are modified. | 2010-02-04 |
| 20100028489 | PRE-FERMENTED SYMBIOTIC MATRIX BASED ON A CEREAL SUSPENSION WITH ENCAPSULATED PROBIOTICS, MANUFACTURE PROCESS AND CORRESPONDING UTILIZATION - The present invention is about a pre-fermented symbiotic matrix based on a cereal suspension, preferably oat, containing encapsulated probiotics and prebiotics, the manufacturing process and the corresponding utilization. The present invention's object is the development of a cereal symbiotic matrix, preferably from oat, pre-fermented with encapsulated probiotics and free and/or encapsulated prebiotics, with the aim of complementing the actual functional food market and solving problems inherent to the reduced shelf-life period of such foods due to loss of probiotic viability to values below the minimum limits needed in order to promote biological activity. Furthermore, the present invention's object is to improve the fermentative process conditions at different levels, namely fermentation time reduction in order to reduce energy consumption during the process and the risk of contamination reduction as well as promote long term microbial stability maintenance. The pre-fermented symbiotic matrix is designed, in particular, for those cases where intolerance and/or allergy to dairy products occur, yet it is further applicable to the pharmaceutical, cosmetic and preferably food industries, including pet food. | 2010-02-04 |
| 20100028490 | BREAD IMPROVER AND USE THEREOF IN MAKING CRUMB-FREE FLAT BREAD - A new bread-making enhancer includes an anti-stale enzyme, an enzyme of the arabinofuranosidase type and a drying component selected from fibres, gums and hydrocolloids. The enhancer is suited for methods for making bread without a soft part such as flat bread or Arab bread. | 2010-02-04 |
| 20100028491 | Aqueous Dough Conditioning Composition - An aqueous dough conditioning composition comprises water, one or more enzymes, salt and sugar characterised in that the composition in substantially free of antioxidant. Preferably, the composition comprises less than 0.05% by wt of antioxidant. The composition may further comprise an oxidant and/or a hydrocolloid. The invention also provides dough comprising the aqueous conditioning composition, and baked products made therefrom. There is also provided the use of salt and sugar to stabilise an aqueous dough conditioning composition comprising one or more enzymes, the composition being substantially free of antioxidant. | 2010-02-04 |
| 20100028492 | METHOD FOR PREPARING A MILK FOR MILK-DAIRY APPLICATIONS, THE MILK OBTAINED BY SAID METHOD AND THE USES THEREOF - The present invention relates to a method, called Mofinazione process, for preparing a milk intended for milk-dairy applications, the milk obtained with said method and the uses thereof. Said method includes an opportune heat treatment of the milk, followed by a pre-maturation concerning the addition and the development within said milk of opportune bacterial strains selected for this purpose, in particular strains with a probiotic valence. | 2010-02-04 |
| 20100028493 | NUCLEOTIDE PYROPHOSPHATASE INHIBITOR AND COENZYME REGENERATING SYSTEMS - The present invention is related to a method for inhibiting nicotinamide coenzyme degradation in a cereal flour or wheat based product, comprising the addition of an effective amount of nucleotide pyrophosphatase inhibitor to said cereal flour based product, product such as a wheat based product. A further aspect of the present invention is a nucleotide pyrophosphatase having an amino acid N-terminal sequence being (G)IDDRHEVDLPPRP. In another aspect of the present invention, a dough comprising a nucleotide pyrophosphatase inhibitor such as pyrophosphate, and optionally a coenzyme regeneration system comprising at least one NAD(P) or NAD(P)H dependent hydrogenase or dehydrogenase is disclosed. Preferably the coenzyme regeneration system comprises (consists of) mannitol dehydrogenase and D-fructose. | 2010-02-04 |
